Recipharm, the contract development and manufacturing organisation (CDMO), has invested in its UK and Ireland presence with the appointment of Shabbir Mostafa to its Business Management team.
Shabbir will join the Sweden-headquartered CDMO as Director, Business Management UK and Ireland with responsibility for supporting customers in the UK and Ireland and driving sales of Recipharm’s manufacturing services.
Commenting on the appointment, Kenth Berg, Vice President Business Management at Recipharm, said: “The UK & Ireland continues to be an important market for Recipharm as we expand our localised presence throughout Europe. Our vision is to be recognised as the best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry and, to achieve this, we are focused on attracting and recruiting excellent people.”
“As we continue to grow as a company, with our focus on decentralised operations, we are highly dependent on talented people at key posts throughout the Recipharm organisation. With his extensive knowledge of the pharmaceutical sector in the UK and Ireland, we believe Shabbir is the perfect addition to our team and will help to drive our business forward in this key market.”
With a PhD in pharmaceutical sciences, Shabbir joins Recipharm from Aesica Pharmaceuticals where he was the Business Development Director with responsibility for global formulation development services and the commercial finished dose business in the UK & Ireland.
During his 15 year career, he has also held positions at PCI Pharma Services, Gattefossé, Patheon and IVAX Pharmaceuticals.
Shabbir said: “Recipharm is highly regarded as a significant force in the pharmaceutical sector and as the CDMO continues to expand its presence and service offering globally, it’s an exciting time to join the team.”
“Recipharm is focused on simplifying the supply chain and managing complexity on behalf of pharmaceutical companies across the world and I look forward to playing my part by supporting our customers in the UK & Ireland.”